This research analyses the compatibility of Indonesian Patent Act with the Trade related Aspect of Intellectual Property Rights (TRIPs) Agreement and the Convention on Biological Diversity (CBD) dealing with Genetic Resources Related to Traditional Knowledge (GRTK). The focus this analyses on whether the new Indonesian Patent Act provides a clear policy on the protection of GRTKF and the development of the biotechnology in Indonesia, particularly on the patentability of genetic resources related inventions, including genes patent. This research found that the new Indonesian Patent Act on GRTK is not only to synergise between the TRIPs Agreement obligation and the CBD compliance, but also adopted patent policies derived from other developed countries particularly in examining the patentability thresholds and exceptions from patentability. Even, in the context of patentability of living organisms, Indonesia adopts a very liberal approach compared to most industrialised countries. This research advises that Indonesian patent policy on GRTK should take into account the richness of this country on biodiversity and the level of biotechnology industry development.
goods (TRIPs Agreement), 1 as one of the pillars of the WTO global trade regime.
To comply with the TRIPs Agreement, Indonesia has already amended its national IPRs law several times, including its Patent Act. 2 Vol. 31; 33 I.L.M. 1197 33 I.L.M. , 1201 33 I.L.M. , 15 April 1994 33 I.L.M. (E (1994 . 2 ' (2000) .; Secretariat-WIPO General Assembly, 'Matter Concerning Intellectual Property and Genetic Resources, Traditional Knowledge, and Folklore' (2000) . Twenty-Sixth (12th Extraordinary) session, Geneva, 25 September -to 3 October, 2000, Document WO/GA/26/6, para 14. See also the Conference of the Parties (COP) of the CBD, in which Intellectual Property Rights (IPRs) is at the heart of discussion, particularly regarding access to genetic resources, benefit sharing, transfer of technology and innovations and traditional knowledge; See also UPOV, 'Access to Genetic Resources and Benefit Sharing -Reply of UPOV to the Notification of June 26, 2003 from the Executive Secretary of the Convention on Biological Diversity (CBD)', adopted by the Council of UPOV at its thirty-seventh ordinary session on October 23, 2003, 3 . See also, the FAO-International Treaty on Plant Genetic Resources (ITP-GR) which entered into force on 29 June 2005, in which a most worthy aspect of the Treaty was the establishment of a multilateral system of access and benefit sharing. 5 After 15 (fifteen) years entered into force, the Act was amended again in 2016 into the new Act Number 13 of 2016 regarding Patent. 9 Surprisingly, one of the most substantial reasons for such amendment was the intensified pressures to fully compliance with TRIPs obligation and the awareness to support access and benefit sharing (ABS), prior informed consent (PIC) provided by the CBD. 10 Indonesia has realised that its GRTK has been utilised by others to develop new and useful inventions, but this country received nothing for such utilization. 11 Accordingly, this new Act has an objective to synergise the TRIPs Agreement and the CBD objectives.
Based on the above background, this research analyses the compatibility of
Indonesia's policy on the patentability of GRTK with the TRIPs Agreement and the CBD. The focus on this analysis is whether patenting GRTK has satisfied the patentability thresholds of novelty, inventive step and industrial applicability in Indonesia. It also analyses whether such patent does not excluded from patentabilty due to contrary to prevailing laws, morality, public order as stipulated under Article 9 of the Indonesian Patent Act. Furthermore, this research also analyses to what extend the principles of CBD such as Prior Informed Consent (PIC), Disclosure of Origin and Benefit Sharing has been accommodated in this Patent Act. Lastly, this research examines the sufficiency of the Patent Act to accommodate the richness of this country on GRTK and whether the Act provides sufficient policy which enables Indonesia to gain benefit from the existing Patent Act to protect GRTK. applicability. 12 By providing those requirements mean that the substance of the Patent Act of 2016 is more or less similar to the TRIPs Agreement. Interestingly, this Act does not use the Indonesian term of invention called 'penemuan' (Indonesian language) anymore, unlike the previous Act. It uses the term 'invensi' as a conversion of the foreign language term 'invention'. 13 Further, unlike the TRIPs Agreement and the Paris Convention 14 which do not define what 'invention' is, this national law has specified the definition of 'invensi' or invention as stipulated under Article 1 (2).
The Patentability on GRTK under Indonesian Patent Act
Invention means "an inventor's idea poured in any activities of solving a specific problem in the field of technology, either in the form of a product or process, or an improvement and development of a product or a process". It means that Indonesia adopts broader concept of invention.
The Act and its explanatory memoranda also do not provide a definition of the 
Patentability Thresholds
The patentability thresholds under the Indonesian Patent Act are similar with other jurisdictions which implement the TRIPs Agreement. As mentioned earlier that the Act provides that a patent may only be granted for an 'invention' that is 'novel', has an 'inventive step' and is 'capable of industrial application', 17 in the field of technology, except for inventions falling under exceptions stipulated in the Article 9. Article 9 of the Indonesian Patent Act of 2016 provides that,Inventions that are not patentable include: a. any process or product of which the announcement and use or the implementation contravenes the prevailing rules and regulations, religious morality, public order or ethics; b. any method of examination, treatment, medication, and or/surgery applied to humans and/or animals; c. any theory and method in the field of science and mathematics; d. all living creatures, except micro-organism, or e. any biological process which is essential in producing plant or animal, except non-biological process or microbiological process.
Based on these thresholds of novelty, inventiveness and industrial applicability, biotechnological inventions are protected, irrespective of whether such inventions are derived from GRTK of other countries of origin. In the absence of a specific reference to invention related to GRTK under Indonesian legal documents and literatures, it can be construed that the requirements of such inventions are the same as those that apply to patent for other types of technological inventions. Because of that, it is important to examine the (3) three patentability thresholds in the context of biotechnological inventions related to GRTK.
• Novelty of GRTK The Act also specified that an invention is not deemed as announced if within the term of maximal 6 (six) months, the inventor has been exploiting the invention in Indonesia for the objectives of R & D experimentation, thesis and dissertation defences, and other scientific meetings to discuss research result in the universities. 22 Furthermore, an invention is also deemed not to be 'announced'
if within the term of 12 (twelve) months before the Filing Date any other person disclosed it by breaching an obligation to keep the invention confidential. 23 Antons observed that this provision is apparently motivated by the doctrine of confidential information which exists in Anglo-American nations and such a doctrine is new under the Indonesian legal system, 24 although a specific law of trade secrets has been enacted in Indonesia. 25 The new Indonesian Patent Act also clearly follows the generally understood and widely adopted rule of patentability that 'discovery' is different It is worthy to note that in the case of processes and techniques of isolation of genetic material and sequences, different jurisdictions apply different approaches. 30 27 Article 7 of the Indonesian Patent Act of 2016. 28 Article 7 (2) of the Indonesian Patent Act of 2016.. Then, the Explanatory Memoranda of the Article 7 (2) clarifies that the meaning of the 'first patent application is filed on the basis of Priority Rights' is the first application proposed in other Paris Convention countries or the WTO Member country. It seems that this Explanatory Memoranda reaffirmed the consistency of Indonesia with Paris Convention. 29 As a developing country, where the development of the biotechnology industry is still not as advanced as the developed countries, the Indonesia's approach in this respect should consider the balance between the need to facilitate the development of biotechnology industry and the people's need to 'enjoy the benefits of scientific progress and its application'. 31 Industrial Applicability of GRTK The term of "industrial applicability" was a subject to question since the previous Patent Act of 2001. Philip Griffith commented that the explanation of 'industrial applicability' under Indonesian Patent Act did not provide clear direction. 32 Griffith predicted that the meaning of the term will be determined on a case by case basis at the examination step and in revocation proceedings in the Commercial Court. 33 Griffith also analysed that this "industrial applicability" requirement under the Indonesian Patent Act has been deliberately kept broad because it is difficult to estimate what kinds of new innovations and technologies will appear and prove to be useful and "what new forms of commercial and industrial uses might be found for those new developments or inventions". 34 In the context of DNA sequence technologies and the isolation of genetic resources and material, if "industrial applicability" is to be broadly interpreted, it means that those technologies and isolation techniques would be regarded as satisfying the "industrial applicability" requirement under the Indonesian Patent Act.
Exceptions to Patentability

• Inventions Contrary to Prevailing Regulations, Public Order and Morality
The Indonesian Patent Act states that a patent shall not be granted to an invention regarding: "Any process or product of which the announcement and use It is perceived that this Article only applies to methods of treatment, but not to medical equipment, devices, and drugs as important elements of treatment.
Accordingly, whether or not an invention is patentable under this provision depends very much on the claim. If the claim is for patented process such as method for treatment, it would be unpatentable, but if the claim is for a product, it would be patentable. This exception is similar to the patent legislation in other jurisdictions 35 Article 9 (a) of the Indonesian Patent Act of 2016. 36 In the absence of any further reference, genes can be patented in Indonesia.
It can be interpreted that what is excluded from patentability under Indonesian
Patent Act is 'human being, animal or plant as a whole'. It can be argued that a part, including genes are subject to patent protection, and plant variety also subject to Plant Varieties Protection (PVP). This exclusion is one which has provoked crucial concerns in the public debate about IPRs in the early 2000 in 38 The Patent Act 1997, Section 4(2) of the United Kingdom.stipulates that: An invention of a method of treatment of the human or animal body by surgery or therapy or of diagnosis practised on the human or animal body shall not be taken to be capable of industrial application. 39 The Patent Office of Canada clearly. stipulates that an invention related to a process of surgery or therapy on living human does not fall under the scope of 'invention' according to Canadian Patent Act of 1985 Section 2., and accordingly they do not fulfil the utility criteria. See Canadian Biotechnology Advisory Committee, 'Patenting of Higher Life Forms and Related Issues'., Report to the Government of Canada, 'Biotechnology Ministerial Coordinating Committee' (Government of Canada, 2002) Indonesia on the basis that patents for such subject matters contravene ethics, religion, and culture of Indonesian values. 43 But, such concern does not appear anymore recently.
Furthermore, in the absence of any reference to the patentability of genes under Indonesian Patent Act, means that it can be interpreted broadly and narrowly, as Subroto and Suprapedi from the IPRs Centre of the Indonesian Science Agency (LIPI) states that: "computer models and related simulations, germ plasmas, cultures, cell sequences, plant, part of plant, seeds, pollen, protein, peptide, metabolite compound, sequence DNA and RNA, genes, probe, plasmid and information related to it" are regarded as IP forms. 44 That argument seems to interpret that the legislation allows that germ plasm, genes, and so forth to be patented. If this interpretation is accurate, the unintended consequences of this loose drafting and lack of analysis may mean that Indonesian patent law is more or less similar to those applied in other developed nations, which follow the principle of "everything under the sun made by man is patentable" except human beings, plants and animals in a whole. This probably as a consequence of lack of clarity of the legislation, but it may also be intentional to enhance the development of biotechnology and industrial application, in particular to increase the number of national "In the absence of any reference to the patentability of living organisms means also that the developing country Indonesia takes an extremely liberal approach in this regard even in comparison to most industrialised countries". 45 (emphasis added) Critics argue that the patentability of those subject matters will be potentially risky for developing countries due to the country's lack of capacity in biotechnology because it may only facilitates the developed nations to get patent protection for their technological innovations in Indonesia, where the local inventors or society have no capacity to compete. It may not increase the number of national patents since the biotechnological development in Indonesia is still at the level of R&D, or otherwise it may also inhibit R & D in Indonesia. Certainly, this is extremely imbalanced of biotechnological development in Indonesia compared to the most developed nations should not be used by Indonesia to take the same approach or even a more "liberal" approach. At least, in providing patent protection for biotechnological inventions, Indonesia should regulate with thresholds not more generous than those provided by the most developed nations.
• Essentially Biological Processes for Production of Plant and Animal
Essentially biological processes for the production of plants and animals are excluded from patentability in Indonesia. 46 In contrast, non-biological processes or microbiological processes are patentable. 47 This exception is in accordance with the TRIPs Agreement. 48 The meaning of "essentially biological process for production of plant or animal" refers to conventional or natural breeding process, like natural transplantation techniques and pollinations. 49 A "non-biological process" or "microbiological process" is defined as transgenic or genetic engineering processes of production of plant or animal which conducted by involvement of chemical process, physics, and the use of micro-organisms or other forms of genetic engineering. 50 The basis for granting patents to inventions related to "micro-organism" or "non-biological processes" and "microbiological processes for the production of plant and animal" is due to the advanced development of biotechnology in the recent decades has resulted in various inventions which had significant advantages to society. Accordingly, patent protection is needed to reward such inventions.
PIC, Disclosure of Origin, Benefit Sharing of the CBD under Indonesian Patent Act
The disclosure of origin and PIC 51 is still at the heart of discussion in a number of international and regional forum. Such concepts are developed under the spirit of the CBD, with the main objective to prevent misappropriation use of patent rights and bio-piracy. In the context of PIC, the Article 15 (5) of the CBD stipulates that "Access to genetic resources shall be subject to prior informed consent of the Contracting Party providing such resources, unless otherwise determined by the Party".
Twenty years ago, several rich biodiversity countries have already amended their patent law by adding disclosure of origin requirement and PIC as a prerequisite for granting patents on biotechnological inventions including inventions related to GRTK. 52 Sadly, although Indonesia is categorised as one of the mega biodiversity countries, such requirements did not exist under the Indonesian Patent Act of 2001.
Surprisingly, the new Act provides provisions on disclosure requirement and benefit sharing. Under this new Act, the nature of disclosure of origin requirement is mandatory, as Article 26 (1) clearly stipulates that "if invention related to and/or derived from genetic resources and/ traditional knowledge, shall clearly and accurately mention the origin of such GRTK in the patent description". The reason for mentioning such source of origin in the patent description is to prevent the claim of such resources and knowledge by other nations, and to support access and benefit sharing. 53 51 The United Nations Environmental Program (UNEP) defines PIC to an activity that is given after receiving full disclosure regarding the reasons for the activity, the specific procedures the activity would entail, the potential risk involved, and the full implications that can realistically be foreseen. See UNEP doc. UNEP/CBD/TKBD/1/2, Oct 18, 1997.[26] . 52 Based on the above provisions, it can be seen that the approach adopted by Indonesia under the new Patent Act on disclosure requirement is in accordance with Indonesia's position at international forums that supports amendment of the TRIPs Agreement to accommodate the principles of PIC, disclosure of origin of genetic resources and benefit sharing. In this context, the Indonesian Government realises that Indonesia has an important position in terms of global biodiversity, and this country is also rich with traditional knowledge growing in traditional communities throughout Indonesia. These valuable resources, should be wisely exploited for the benefit of the communities and the State, while the sustainable and conservation of environment should also be maintained for future generation. 54 Article 132 (1) b of the Indonesian Patent Act of 2016.
Conclusion
The new Indonesian Patent Act is drafted as a direct interpretation to the TRIPs Agreement and adopted some developed nation legislations on patents especially for substantial aspects, like patentability thresholds, exceptions from patentable inventions, the concept of invention, and the patentability of inventions related to GRTK. Even though in those areas the TRIPs Agreement provides some flexible room for interpretation in line with the level of biotechnological development, Indonesia does not use this opportunity. Otherwise, there is an indication that Indonesia has adopted a similar approach to other developed nations or even overly liberal approach which more suited to a country with greater degree of economic and biotechnological development. Because of that, the new Indonesian Patent Act of 2016 is still insufficient to deal with patentability of GRTK and the development of biotechnology industry in Indonesia. It is uneasy for GRTK to fulfil the patentability thresholds of novelty and inventiveness under Indonesian Patent Act and the patentability on genes is still unclear.
The new Indonesian Patent Act also still insufficient to accommodate both the richness of this country on GRTK and the level of biotechnological development of Indonesia. Because of that, it is uneasy for this country to gain benefit from the existing of new Patent Act to utilize the richness of GRTK since the level of biotechnological development is not as advanced as developed nations. But the substance of the new Indonesian Patent Act is similar to the Patent Acts of many developed countries which are advanced in modern biotechnology industry. 
